Opinion|Videos|July 29, 2024
Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.
Advertisement
Episodes in this series
- What other potential advances are you excited about in the HR+ BC space?
Advertisement
Related to this article
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
4
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
5